Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07492316 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)

Name: RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) — clinical trial record (NCT07492316)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: PNOC020 rMB

StatusActive, Not Recruiting

PhasePhase 1

SponsorUniversity of Florida

Started2026-04-24

View on ClinicalTrials.gov ↗

Amendment history

2026-09-30

Enrollment closed, study ongoing

2026-06-26

Study Status v2

Start dateestimated 2026-05-15→confirmed 2026-04-24

2026-04-22

Study Status, Contacts/Locations v1

Recruitment opened

Study sites0→1

2026-03-19

Original filing

University of Florida

325 trials monitored

See 23 trials at risk

The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in pediatric patients with recurrent/progressive Medulloblastoma (MB)

Trial Details

NCT Number	NCT07492316
Lead Sponsor	University of Florida Collaborators: Pediatric Neuro-Oncology Consortium
Conditions	Recurrent Medulloblastoma
Enrollment	24 participants
Start Date	2026-04-24
Primary Completion	2030-09-01 (estimated)
Study Completion	2031-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-09-29